Bin Wu

TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.

TL;DR: Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivOSidenib was well tolerated, and this study shows the clinical benefit of targeting IDH1 mutations in advanced,IDH1-mutant cholangiocarcinoma.

TL;DR: In this article, the authors measured 2-HG, mIDH2 allele burden, and cooccurring somatic mutations in sequential patient samples from the clinical trial and correlated these with clinical response.

TL;DR: Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed and clearance of mutant-IDH2 clones was also associated with achievement of CR.

TL;DR: Ivosidenib monotherapy was well tolerated and induced durable remissions and transfusion independence in patients with newly diagnosed acute myeloid leukemia (AML).